Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER–Medicare database

Hepatology

Volumn 65, Issue 1, 2017, Pages 122-133

  Parikh, Neehar D ^a   Marshall, Vincent D ^a   Singal, Amit G ^b   Nathan, Hari ^c   Lok, Anna S ^a   Balkrishnan, Rajesh ^d   Shahinian, Vahakn ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CLINICAL PRACTICE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICARE; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CANCER REGISTRY; CARCINOMA, HEPATOCELLULAR; ECONOMICS; FACTUAL DATABASE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 85005896284     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28881     Document Type: Article

References (34)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118–1127.
2. Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
4. DA Fonseca LG, Barroso-Sousa R, Bento AD, Blanco BP, Valente GL, Pfiffer TE, et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:793–796.
5. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609–617.
6. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161:170–180.
7. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-3–18.
8. Huskamp HA, Keating NL. The new medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med 2005;20:662–665.
9. Fritz AG. International Classification of Diseases for Oncology: ICD-O. 3rd ed. Geneva, Switzerland: World Health Organization, 2000.
10. Artinyan A, Marshall CL, Balentine CJ, Albo D, Orcutt ST, Awad SS, et al. Clinical outcomes of oncologic gastrointestinal resections in patients with cirrhosis. Cancer 2012;118:3494–3500.
11. Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:64–70.
12. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948–963.
13. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology 2013;57:112–119.
14. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1339–1341.
15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253–1258.
16. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518–528.
17. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796–797.
18. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:309–319.
19. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7:723–740.
20. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42.
21. Therneau T. A package for survival analysis in S. Version 2.38. Rochester, MN: Mayo Clinic; 2015.
22. Hansen BB, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Stat Sci 2008;23:219–236.
23. Bowers J, Fredrickson M, Hansen B. RItools: randomization inference tools. R package version 0.1-12. 2014.
24. Harrell FE. rms: Regression modeling strategies. R package version 4.3-1. 2015.
25. Fox J, Weisberg S. An R companion to applied regression. 2nd ed. Thousand Oaks, CA: SAGE Publications; 2011.
26. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2015.
27. Marrero RL JA, Ye S-L, Kudo M, Bronowicki J-P, Chen X-P, Dagher L, et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction. In: Program and Abstracts of the 49th Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL.
28. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014;5:e45.
29. ClinicalTrials.gov. Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (BOOST). https://clinicaltrials.gov/ct2/show/NCT01405573. Accessed on: March 15, 2016.
30. Zhang P, Yang Y, Wen F, He X, Tang R, Du Z, et al. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2015;27:853–859.
31. Camma C, Cabibbo G, Petta S, Enea M, Iavarone M, Grieco A, et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 2013;57:1046–1054.
32. Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287–1295.
33. Hartley D, Quam L, Lurie N. Urban and rural differences in health insurance and access to care. J Rural Health 1994;10:98–108.
34. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol 2016;34:1787–1794.